Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Hypercholesterolemia
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Phone Counseling, Standard Clinical Care; Behavioral · Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 17 Years and older
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Dry Eye Disease, Meibomian Gland Dysfunction
Interventions: Sunflower lecithin, Olive oil; Dietary Supplement
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: torcetrapib/atorvastatin, ezetimibe/simvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 123
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more

Conditions: Cardiovascular Disease
Interventions: Niacin Extended Release; Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions: bempedoic acid, placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more

Conditions: Type 2 Diabetes
Interventions: DIO-902; Drug
Lead sponsor: DiObex; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more

Conditions: Gout, Hyperuricemia
Interventions: Subsidy for food purchases and dietitian education; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Woodlawn, Maryland • Boston, Massachusetts

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Healthy Volunteers, Statins, Immune Modulation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia
Interventions: Evolocumab, Placebo to Evolocumab; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 55
States / cities: Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more

Conditions: Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 7,658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases, Pharmacists, Placebo Effect
Interventions: Virtual Statin Management (VSM); Other
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 80 Years
Enrollment: 898 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cardiovascular Disease, Cigarette Smoking
Interventions: Subject's usual brand (UB) tobacco product; Other
Lead sponsor: R.J. Reynolds Tobacco Company; Industry
Eligibility: 26 Years to 49 Years · Male only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: Dietary intervention; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Low Risk (0-10% Chance) of Developing Cardiovascular Disease Within 10 Years Based on Risk Factors, Moderate Risk (10-20% Chance) of Developing Cardiovascular (Heart) Disease Within 10 Years Based on Risk Factors
Interventions: Interactive Cholesterol Advisory Tool, Study physician visits; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Cancer
Interventions: Lovastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Prescreening, Screening and Enrollment, Baseline, Interpret BMI, Interpret HbA1c, Interpret lipid panel and assess other risk factors, Assess 10 year risk of cardiovascular event, Recommendations, Follow-Up; Other · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Ezetimibe, Phytosterols + ezetimibe, Placebo; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Interventions: Rosuvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lipoprotein (a)
Interventions: Venipuncture; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Cerebrotendinous Xanthomatosis
Interventions: chenodeoxycholic acid, lovastatin; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients

Nurse Telephone Management of Cholesterol in Diabetes

Effect of Sunflower Lecithin Supplementation on Meibomian Gland Function in Adults With Dry Eye Disease

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Effects of Niacin Therapy on Lipoprotein Composition and Function

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

The Diet Gout Trial

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

Patient and Provider Assessment of Lipid Management Registry

A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.

Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers

Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Interactive Cholesterol Advisory Tool

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Cardiometabolic Screening Program

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Phytosterols, Ezetimibe, and Cholesterol Metabolism

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

Lipid Screening Study

Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis